Felice Giuliante

Plain English
This study looked at different types of cholangiocarcinoma (CCA), a type of bile duct cancer, to see how their characteristics affect patient outcomes. Researchers analyzed data from 293 patients and found that a specific subtype of intrahepatic CCA (called PAS HIGH LBD iCCA) had a much worse chance of survival over five years compared to others, with significantly poorer outcomes tied to this subtype. Understanding these differences helps doctors better predict patient prognosis and tailor treatments accordingly. Who this helps: This benefits patients with cholangiocarcinoma and their doctors by providing clearer insights into their condition.

Plain English
This study compared two types of chemotherapy given before surgery for patients with colorectal cancer that has spread to the liver. It found that patients who received the FOLFOXIRI treatment had a higher rate of successful major liver surgeries (44.4% compared to 35.3%) and better long-term survival rates (66.6% over five years compared to 56.4%) despite experiencing more significant blood loss and a few more transfusions during surgery. This matters because choosing the right chemotherapy before surgery can improve outcomes for patients with liver metastases. Who this helps: Patients with colorectal liver metastases.

Plain English
This study looked at the outcomes of patients with colorectal liver metastases (CRLM) who underwent two different types of minimally invasive surgeries: those who had combined colorectal and liver surgery and those who only had liver surgery. Among the 2,286 patients analyzed, those who had the combined surgery faced a higher risk of major complications (11.55% compared to 5.11%) and longer operations (385 minutes versus 270 minutes). These findings emphasize that careful selection of patients is crucial since combining surgeries can increase risks and may not be suitable for everyone. Who this helps: This helps doctors in deciding the best surgical approach for patients with colorectal liver metastases.

Plain English
This research looked at the outcomes of surgically removing parts of the liver (liver resection) in patients with liver metastases that originate from tumors other than colorectal cancer. The findings showed that patients with neuroendocrine tumors had the best survival rates, living an average of 7 to 10 years after surgery, while those with gastrointestinal stromal tumors lived about 6 to 7.5 years. These results are important because they highlight that certain patients can benefit significantly from surgery, especially if their cancer has specific favorable characteristics. Who this helps: This information helps patients with certain types of non-colorectal liver metastases and their doctors in making treatment decisions.

Plain English
This study looked at the outcomes of patients who had to switch from minimally invasive liver surgery to open surgery, focusing on whether this change happened in emergencies or planned procedures and how the type of surgery (robotic or laparoscopic) affected the results. Out of over 10,500 procedures, 719 (6.8%) required conversion, with emergency cases resulting in more serious complications, including higher blood loss and even a mortality rate of 7.7% for robotic cases. This is important because it shows that planned conversions are generally safe, but emergency conversions can lead to worse outcomes, making it crucial for doctors to manage timing carefully. Who this helps: This benefits patients undergoing liver surgery and their doctors.

Plain English
This study explored how to create and use patient-derived organoids (PDOs) from liver cancer patients to better understand the disease and develop personalized treatments. The researchers successfully established organoids from surgical samples with good consistency to the original tumors, showing a high success rate in growing these organoids for further study. This matters because it opens up new possibilities for testing treatments and discovering new biomarkers in liver cancer. Who this helps: This helps patients with liver cancer and their doctors.

Plain English
This study looked at the outcomes of a specific liver surgery called laparoscopic right posterior sectionectomy, which is performed minimally invasively. Researchers analyzed data from 854 patients across 57 centers worldwide from 2015 to 2021 and set standards for things like surgery time and complications. They found that low-risk surgeries had an average operation time of about 351 minutes and a 4% rate of perfect outcomes, providing doctors with important benchmarks for success. Who this helps: This benefits doctors performing liver surgeries and their patients.

Plain English
This study compared two types of surgical techniques—robotic and laparoscopic minor liver surgery—specifically for certain parts of the liver. Out of over 10,000 patients analyzed, those who underwent robotic surgery had less blood loss (75 mL vs. 100 mL), reduced need for blood transfusions (3.1% vs. 5.4%), shorter hospital stays (4 days vs. 5 days), and fewer serious complications (2.5% vs. 4.6%). These findings show that robotic liver surgery can be safer and more efficient than traditional laparoscopic methods, especially for patients with liver conditions. Who this helps: This helps patients undergoing minor liver surgery and their doctors by providing better surgical options.

Plain English
This study looked at the effectiveness of a system called the IMM complexity classification, which ranks laparoscopic liver surgeries based on how complex they are. Researchers analyzed data from 22,252 patients across 64 centers worldwide and found that more complex surgeries took longer and resulted in more complications; for example, the average surgery time, blood loss, and hospital stay all increased with the complexity level. This matters because it helps doctors better understand how to prepare for these surgeries and manage patient care based on the complexity. Who this helps: This helps patients and doctors preparing for laparoscopic liver surgeries.

Plain English
This study looked at how to predict liver failure after surgery in patients with liver cancer using advanced computer techniques and scans. Researchers examined 500 scans and found that 17 patients (or 3.4%) experienced liver failure after surgery. The best predictive model (a combination of two machine-learning approaches) had an impressive accuracy rate of 89.2%, which could help doctors identify which patients are likely to recover well from surgery and which ones might face complications. Who this helps: This helps patients with liver cancer and their doctors in making better treatment decisions.

Plain English
This study compared two types of liver surgery for patients with liver cancer, known as hepatocellular carcinoma. It found that minimally invasive surgery (MALS) resulted in fewer complications after simpler procedures (53.2% of cases) and fewer major complications for more complex cases (20.5% of cases). However, for the most complex procedures (26.2%), MALS increased the risk of serious complications, especially in lower-volume hospitals. These findings highlight that the type of surgery and the hospital's experience can significantly impact patient recovery after liver cancer surgery. Who this helps: This information helps patients and doctors make more informed choices about liver cancer surgery options.

Plain English
This paper responds to a previous commentary on a study about blood purification treatments for patients with severe liver issues after they have had a liver transplant or major liver surgery. The original study found that while these treatments can improve blood quality, they are not always effective in every case, highlighting the need for better methods. This research is important because it helps identify limitations in current treatments and could lead to improvements in patient care. Who this helps: This benefits patients recovering from liver transplants or surgeries.

Plain English
This study compared two types of liver surgery for patients with a type of liver cancer called hepatocellular carcinoma (HCC) that has not spread to other organs. Researchers analyzed data from 627 patients, finding that minimally invasive liver surgery (MILS) did not lead to more complications or longer hospital stays than traditional open liver resection (OLR). However, MILS resulted in significantly fewer blood transfusions and less fluid buildup after surgery. Who this helps: This benefits patients with non-metastatic liver cancer by offering a safer surgical option.

Plain English
This study looked at the results of liver surgeries performed on 164 patients with a specific liver stone condition called hepatolithiasis. Researchers found that using minimally invasive techniques, which are less invasive than traditional surgery, made a significant difference: these patients experienced fewer complications and shorter hospital stays, with 60% of surgeries in the latest period being minimally invasive. There was a 20% rate of recurrence for stones after surgery, particularly when the stones were not fully cleared. Who this helps: This research benefits patients suffering from liver stones and doctors by providing insights into effective surgical approaches.

Plain English
This study looked at different ways to evaluate the risks associated with liver surgery for patients with liver cancer in Italy, focusing on 3,280 surgeries. Researchers found that traditional classifications for liver surgery, which rely on how much liver tissue is removed, work well for open surgeries but do not effectively predict outcomes for minimally invasive surgeries—where patient safety is harder to assess. This is important because understanding these risks can help improve patient care and surgical planning. Who this helps: This benefits patients undergoing liver surgery and their doctors.

Plain English
This study examined how to predict the risk of lymph node metastases (LNM) in patients with a specific type of liver cancer, known as intrahepatic cholangiocarcinoma, who are scheduled for surgery. Researchers reviewed data from 693 patients and found that factors such as the level of a blood marker (CA 19-9), the condition of lymph nodes seen in imaging tests, age, and the extent of the tumor were linked to the likelihood of LNM. The model developed to assess risk showed fairly high accuracy, which can help doctors make better decisions about treating these patients. Who this helps: This benefits patients undergoing surgery for intrahepatic cholangiocarcinoma and their doctors.

Plain English
This study looked at robotic liver surgeries to set global standards for successful outcomes based on data from over 5,200 patients treated in 51 medical centers worldwide. The researchers established benchmark indicators for four types of surgeries, finding that about 31% of the cases qualified as low-risk, with specific operation times ranging from 190 to 474 minutes and very low rates of complications and mortality. Establishing these benchmarks helps hospitals measure their performance against the best practices, ultimately aiming to improve patient care. Who this helps: Patients undergoing robotic liver surgery and their doctors.

Plain English
This study looked at how MRI scans can help predict how well colorectal cancer that has spread to the liver responds to chemotherapy before surgery. Researchers found that out of 131 patients who showed some signs of tumor shrinkage on their scans, 45% actually had no real tumor reduction when examined after surgery. Using a combination of clinical data and advanced MRI analysis produced an accuracy rate of 77% in predicting true tumor response, which is better than using clinical data alone. Who this helps: This benefits patients with colorectal liver metastases and their doctors by providing a more accurate way to assess treatment effectiveness before surgery.

Plain English
This study looked at the outcomes of liver surgery in patients with colorectal cancer that has spread to the liver (known as colorectal liver metastases). Researchers examined data from over 12,000 patients treated at 43 medical centers between 2000 and 2022 and found that 90-day death rates after surgery were under 5%. They also discovered that most patients had a high chance of surviving for one year (over 85%) and varying chances of surviving for five years depending on the number of metastatic tumors, with survival rates ranging from 4% to 67%. Who this helps: This research benefits patients with colorectal liver metastases and their doctors by providing clear benchmarks for evaluating treatment options.

Plain English
This study looked at how patients with colorectal cancer that has spread to the liver did when treated at a specialized medical center. Researchers analyzed data from 613 patients and found that those who received comprehensive care at the center had a better chance of living at least five years after treatment—54.5% compared to 44.6% for those who did not receive the same level of internal management. This matters because better management can lead to improved survival rates for patients facing this challenging condition. Who this helps: Patients with synchronous colorectal liver metastases.

Plain English
This study examined how surgeons around the world use preoperative chemotherapy to treat a type of liver cancer called intrahepatic cholangiocarcinoma (iCCA). Out of 167 surgeons surveyed, 91.6% stated they typically use chemotherapy for patients whose tumors are initially inoperable, and 74.8% would use it to improve surgical outcomes. Defining when a tumor cannot be removed is complicated, but using chemotherapy can help shrink tumors and choose the best candidates for surgery, potentially increasing the chances of successful removal. Who this helps: This benefits patients with intrahepatic cholangiocarcinoma.

Plain English
This study looked at how different surgical methods for removing incidental gallbladder cancer (iGBC) affect patients' recovery and long-term health outcomes. Researchers compared traditional open surgery with minimally invasive techniques used on 95 patients over 25 years and found that while minimally invasive surgery took longer, it resulted in shorter hospital stays without affecting the chances of surviving cancer or having it come back. Overall, the type of surgery didn't change patients' long-term outcomes; instead, factors like tumor stage and lymph node involvement were more important. Who this helps: This benefits patients with incidental gallbladder cancer and surgeons performing these procedures.

Plain English
This study focused on methods to encourage the liver to grow larger before surgery to remove part of it (hepatectomy). Researchers found that there are many different techniques being used by surgeons, but there's a lack of consistent safety standards or guidelines for how to apply them. Establishing clear guidelines for these techniques is important because it could improve patient outcomes during liver surgeries. Who this helps: This helps patients undergoing liver surgery.

Plain English
This study looked at patients who had surgery for a type of liver cancer called intrahepatic cholangiocarcinoma (ICC) to see if certain pre-surgery health factors could predict if their cancer would come back quickly, within six months. Researchers analyzed data from 83 patients and found that about 20% (17 patients) experienced very early recurrence, which is linked to a much worse survival rate—0% for those with early recurrence compared to nearly 49% for those without. The study concluded that just looking at pre-surgery health factors is not enough to predict early cancer recurrence, suggesting a need for better methods that consider more detailed patient data. Who this helps: This information is valuable for doctors and patients facing surgery for intrahepatic cholangiocarcinoma.

Plain English
This study looked at surgery results for patients with treatable gallbladder cancer across 41 hospitals worldwide. They found that only 30.7% of patients achieved what they call a "textbook outcome," which is a successful surgery without significant complications or fatalities. Importantly, surgeries using robotic techniques had better results compared to traditional laparoscopic ones, leading to higher success rates and lower complications. This information is valuable because it helps hospitals improve surgical outcomes, ultimately benefiting patients facing this challenging cancer. Who this helps: Patients with gallbladder cancer.

Plain English
The NONCOLMET study looked at the outcomes of patients with non-colorectal liver metastases (cancer that has spread to the liver from other parts of the body) who underwent liver surgery. The researchers aimed to gather detailed information about these patients to understand their survival rates and other important factors. They found that having a clear registry and data from patients who had surgery might help improve treatment guidelines and patient selection for surgery. Who this helps: This benefits patients with non-colorectal liver metastases who may need surgery, as well as doctors making treatment decisions.

Plain English
This study looked at how the treatment of gallbladder cancer affects survival rates. Researchers found that patients who had surgery to remove at least six lymph nodes and received capecitabine chemotherapy lived longer and had better chances of surviving without cancer returning. Specifically, those who received both treatments had a survival time of 15 months compared to just 7.5 months for those who did not. Who this helps: This benefits gallbladder cancer patients by improving treatment options and outcomes.

Plain English
This study looked at how a team of different cancer specialists, called a multidisciplinary tumor board (MDTB), affects the treatment of colorectal cancer. They reviewed 1,150 cases between 2019 and 2023 and found that after the MDTB meetings, treatment decisions changed in 325 cases, leading to a discrepancy rate of 28.3%. These changes, particularly in decisions about imaging, surgery, and radiation, show that teamwork among specialists can significantly improve treatment planning for patients. Who this helps: This helps patients with colorectal cancer by ensuring they receive the best possible treatment options.

Plain English
This study looked at how well patients with metastatic colorectal cancer (mCRC) do after having surgery to remove tumors, specifically focusing on those who had the surgery done more than once. Out of nearly 1,600 patients, 143 underwent at least two surgeries; they had a median time without cancer recurrence of 8.2 months after the second surgery and a 5-year survival rate of 73.1%. The research highlights that repeated surgeries can significantly improve survival for certain patients, and using a scoring system can help doctors choose who would benefit most from such procedures. Who this helps: This helps patients with metastatic colorectal cancer and their doctors.

Plain English
This study reviewed 105 cases of GAPO syndrome, a rare genetic disorder that affects growth, skin, teeth, and vision. The researchers found that this condition has multiple symptoms mainly involving bones, skin, and eyes and is caused by specific genetic changes. Understanding GAPO syndrome's characteristics is crucial because it can lead to better early diagnosis and treatment strategies. Who this helps: This helps patients with GAPO syndrome and their healthcare providers.

Plain English
This study compared two different surgical techniques for removing liver tumors in patients with hepatocellular carcinoma (HCC): robotic liver resection (RLR) and laparoscopic liver resection (LLR). Researchers looked at outcomes from 647 patients and found that RLR resulted in wider surgical margins (10 mm vs. 5 mm), lower rates of conversion to open surgery (2.1% vs. 8.5%), shorter hospital stays (4 days vs. 5 days), and significantly better recurrence-free survival after five years (46.8% for RLR compared to 24.0% for LLR). This is important because better margins and lower recurrence rates can lead to improved long-term outcomes for patients with HCC. Who this helps: This helps patients with liver cancer and their doctors by providing insights into more effective surgical options.

Plain English
This study looked at gallbladder cancer surgery to find out when the surgery might not help patients. Researchers analyzed the data from 788 patients and found that 107 of them (about 14%) had what’s called "futile surgery,” meaning they either had their cancer come back quickly or died shortly after the operation. The results showed that patients with advanced tumors or those who had more complicated surgeries faced a higher risk of these poor outcomes, with those who had successful surgery living much longer—about 57 months compared to 6.8 months for those with futile surgeries. Who this helps: This benefits patients with gallbladder cancer and their doctors by helping to decide when surgery is a good option.

Plain English
This study examined the effects of a specific type of surgery called oncologic extended resection (OER) on patients with advanced gallbladder cancer, specifically those with T3 and T4 stages. Researchers looked at data from 419 patients and found that those with T4 cancer had a higher risk of complications and a much lower chance of surviving three years after surgery (only 4%) compared to those with T3 cancer (33%). Understanding these outcomes helps doctors make better decisions about whether aggressive surgery is appropriate for individual patients with advanced gallbladder cancer. Who this helps: This helps doctors and patients by providing insights into treatment options and their risks.

Plain English
This study looked at how well two different tests for blood clotting, conventional coagulation tests and a new device called TEG6s, performed for patients recovering from liver surgery for cancer. The researchers found that while 41% of patients were labeled as having low blood clotting ability by traditional tests, only 10% had the same low reading from the TEG6s device. This difference is important because it indicates that TEG6s may provide a more accurate picture of a patient's clotting ability right after surgery, which could help doctors make better decisions about treatment and monitor postoperative bleeding. Who this helps: This benefits patients recovering from liver resection surgery and the doctors caring for them.

Plain English
This study looked at two treatment options for patients with small single liver tumors called hepatocellular carcinoma (HCC) that are 3 cm or smaller. Researchers compared surgical removal of the tumor (laparoscopic resection) to a less invasive method using heat to destroy the tumor (thermoablation) in 1,465 patients. They found that patients who had the tumor surgically removed lived longer (median of 93 months) and had a longer time without the cancer returning (39 months) compared to those who had thermoablation (median overall survival of 60 months and recurrence-free survival of 26 months). Who this helps: This research benefits patients with small liver tumors by highlighting the importance of surgical options for better long-term outcomes.

Plain English
This study examined the Iwate difficulty scoring system, which assesses how challenging laparoscopic liver surgeries are based on 12 points and four difficulty levels. Researchers analyzed data from 14,759 patients who had this surgery at 64 hospitals worldwide and found that as the difficulty score increased, so did complications, longer surgery times, and higher rates of serious issues after surgery. Specifically, they confirmed that both the four levels and the 12-point scale of the scoring system are effective in predicting surgical outcomes, leading to more informed surgical decisions. Who this helps: This benefits patients by improving the safety and effectiveness of their liver surgeries.

Plain English
This study looked at a rare condition called hepatic splenosis, which can look like liver cancer on imaging tests. Researchers reviewed past cases and presented one of a 52-year-old man who had a liver lesion that seemed like cancer but turned out to be splenic tissue in the liver. Recognizing splenosis in patients without liver disease can avoid unnecessary surgeries and help doctors manage these cases better. Who this helps: Patients who have had their spleen removed and develop liver lesions.

Plain English
This study looks at various factors that can help predict how well patients will do after surgery to remove liver tumors caused by hepatocellular carcinoma (HCC). It found that while traditional markers like certain tumor characteristics and alpha-fetoprotein levels are still important, newer markers like inflammation indicators and liquid biopsy techniques show promise for predicting outcomes. About 70% of patients experience a recurrence of the cancer after surgery, so finding reliable ways to assess prognosis is crucial for guiding treatment decisions. Who this helps: This helps doctors and patients dealing with liver cancer.

Plain English
This study looked at two surgical methods—right hepatectomy and left hepatectomy—for treating Klatskin tumors, which are difficult bile duct tumors. The researchers reviewed 21 studies and found that while both surgery types can achieve cancer-free margins, left hepatectomy may offer slightly better outcomes and fewer complications for patients with early-stage tumors (Klatskin types I and II). This information is important for doctors making treatment decisions, as it highlights the potential benefits of choosing one surgical approach over the other based on the specific type of Klatskin tumor. Who this helps: This helps patients with Klatskin tumors and the doctors who treat them.

Plain English
This study looked at how different surgical methods for liver removal affect liver damage after surgery. It found that patients who had minimally invasive liver surgery (MILS) had much lower levels of a liver enzyme called ALT on the first, third, and fifth days after surgery compared to those who had traditional open surgery: for example, the median ALT level was 301 in the open surgery group versus 187 in the MILS group on the first postoperative day. This matters because lower ALT levels indicate less liver injury, which can lead to quicker recovery and fewer complications. Who this helps: This benefits patients undergoing liver surgery.

Plain English
This study surveyed 46 hospitals in Italy to understand how liver hypertrophy techniques—methods that help the liver grow before surgery—are being used. They found that 27% of liver surgeries involved these techniques, with 6.2% specifically requiring them, and that the most common reason for patients dropping out of treatment was disease progression in over 58% of cases. The findings show that while these techniques are important for improving patients’ chances of surgery, there is still a lack of uniform guidelines on when to use them. Who this helps: This information benefits doctors and medical centers working with liver surgery patients.

Plain English
This study focused on how to treat large liver tumors (specifically larger than 5 cm) effectively. Researchers looked at 535 patients and found that performing major liver surgery led to more serious complications without providing better long-term survival compared to smaller, less invasive surgeries. They concluded that, when possible, smaller surgeries should be the preferred option since they result in fewer complications while offering similar outcomes. Who this helps: This benefits patients with large liver tumors by reducing their risk of complications from surgery.

Plain English
This study looked at the benefits of laparoscopic (minimally invasive) surgery compared to open surgery for removing liver lesions in specific areas of the liver called anterolateral (AL) and posterosuperior (PS) segments. The research found that laparoscopic surgery resulted in less blood loss, fewer complications, and shorter hospital stays. For example, patients who had laparoscopic surgery in the AL segment experienced 195 mL less blood loss and had a 4.8% lower rate of overall complications compared to those who had open surgery. Who this helps: This helps patients needing liver surgery by providing insights into which surgical approach may lead to better outcomes.

Plain English
This study looked at patients who underwent liver surgery to see how surgical complexity and nutritional health could help predict complications after the procedure. Out of 1,258 patients, 570 (about 45%) had complications, with 506 needing treatment. Researchers found that using a model based on liver surgery complexity and certain nutritional factors (like cholinesterase and albumin levels) could predict complications more accurately than standard nutritional assessments. For example, patients with good cholinesterase levels were estimated to have 5-15% fewer complications than those with lower levels. Who this helps: This helps doctors better predict and manage complications for patients undergoing liver surgery.

Plain English
This study looked at how to predict early cancer recurrence in patients with a specific type of liver cancer called peri-hilar cholangiocarcinoma (PCC) by creating a tool called the Preoperative Recurrence Score (PRS). Researchers found that certain factors, like tumor size over 18 mm and involvement of nearby blood vessels or lymph nodes, significantly increased the risk of cancer returning after surgery. For instance, patients with a high PRS had a one-year recurrence rate of 80% in one group, highlighting the tool's effectiveness in assessing risk before surgery. Who this helps: This helps patients and doctors make better decisions about surgery for liver cancer.

Plain English
This research focuses on using a new method called organoids to study liver cancer (hepatocellular carcinoma, or HCC), which has many variations and a complex environment that makes it hard to replicate in traditional lab settings. The findings showed that organoids can effectively mimic the cancer's behavior and interactions with the immune system, which is crucial for testing how well different treatments might work. This matters because it helps researchers better understand liver cancer and improve treatment options for patients. Who this helps: Patients with liver cancer and their doctors.